Archives
-
IPA-3 for Reliable Pak1 and Cell Assays
2026-09-22
This scenario-driven guide explains how IPA-3 (SKU B2169) can support Pak1 autophosphorylation inhibition, kinase activity assays, and interpretation of cell viability or cytotoxicity data. It emphasizes solvent control, biochemical-versus-cellular potency, product selection, and the limits of translating in vitro findings into cancer biology research or spinal cord injury recovery research.
-
PNU 74654: Wnt Signaling Pathway Inhibitor
2026-09-21
PNU 74654 is a small-molecule Wnt signaling pathway inhibitor for laboratory studies of Wnt/β-catenin signaling inhibition. Its product specifications support controlled formulation and storage, while peer-reviewed evidence defines relevant pathway biology without directly validating PNU 74654 in cancer or stem cell models.
-
S63845: Translating MCL1 Dependency Into Apoptosis
2026-09-21
S63845 offers a selective way to test whether cancer cells are functionally dependent on MCL1. This thought-leadership perspective connects mitochondrial apoptosis biology with experimental design, combination strategy, and translational decision-making across hematological and pancreatic cancer models.
-
GDC-0941: PI3K Inhibitor Mechanism and Workflow
2026-09-20
GDC-0941 is an orally bioavailable PI3K inhibitor with nanomolar activity against PI3Kα and PI3Kδ. Its reported ATP-site mechanism, pathway readouts, cancer-cell assays, and xenograft results support its use as a research tool for PI3K/Akt pathway inhibition, while the available evidence does not establish clinical efficacy or direct activity in liver cancer stem cells.
-
XAV-939: Wnt/β-Catenin Research Guide
2026-09-19
XAV-939, also known as NVP-XAV939, is a cell-permeable TNKS1/TNKS2 inhibitor that stabilizes axin and suppresses β-catenin signaling. This guide connects its biochemical profile and application-specific parameters with evidence from cancer research, fibrotic disease research, bone biology, and human cardiac reprogramming.
-
miR-18a, ALOXE3, and Ferroptosis in Glioblastoma
2026-09-18
The reference study identifies a miR-18a/ALOXE3 axis that promotes glioblastoma by suppressing ferroptotic cell death and enhancing migration through 12-HETE–linked Gs protein signaling. Its integrated use of human tumor analyses, genetic perturbation, orthotopic models, lipid mediator measurements, and pathway studies provides a useful framework for investigating lipid metabolism in glioblastoma.
-
RepSox for iPSC Differentiation Workflows
2026-09-18
RepSox provides a selective way to interrogate ALK5-dependent TGF-β biology in reprogramming, differentiation, and platelet-production experiments. This guide separates established RepSox evidence from testable extensions of a 2026 hiPSC-to-platelet workflow, with practical setup and troubleshooting advice.
-
Cy5 amine (non-sulfonated): Labeling Guide
2026-09-17
Cy5 amine (non-sulfonated), SKU A8143, provides a primary amino group for covalent attachment to activated biomolecules while delivering red/far-red fluorescence near 662 nm. It is suited to research workflows such as fluorescence microscopy, flow cytometry, and molecular tracking, but must first be dissolved in DMSO or ethanol because it is insoluble in water and is not intended for diagnostic or medical use.
-
Vemurafenib (PLX4032, RG7204) in Melanoma Assays
2026-09-17
Learn how Vemurafenib (PLX4032, RG7204), SKU A3004, can improve experimental interpretation in BRAF-mutant melanoma viability and resistance studies. This scenario-based guide covers assay design, solvent handling, dose-response analysis, resistance biology, and practical product-selection criteria.
-
C9orf72 Poly-GA, ERK1/2, and Tau Pathology
2026-09-16
A 2025 cellular study links C9orf72-derived poly-glycine-alanine [(GA)50] to ERK1/2 binding, increased ERK1/2 phosphorylation, tau pathology, and neuronal cell death. Pharmacological intervention with U0126 reduced tau phosphorylation, aggregation, and cell death, identifying ERK1/2 signaling as a mechanistic connection between DPR toxicity and tau dysregulation.
-
Wortmannin in HCC Ferroptosis Assays
2026-09-16
Wortmannin is a powerful PI3K inhibitor for testing how PI3K/Akt signaling controls ferroptosis resistance in hepatocellular carcinoma. This article translates recent FAT4–PI3K/AKT findings into a rigorous assay strategy that separates pathway causality from exposure and off-target effects.
-
Thioguanine Workflows for Cancer and Viral Assays
2026-09-15
Thioguanine, also called 6-thioguanine, supports lineage-aware leukemia testing, cancer cell proliferation inhibition, and cell-based EV71 virus inhibition studies. This practical guide combines published resistance profiling with formulation, assay-design, and troubleshooting strategies for more reproducible results.
-
MVC Activates RhoA/ROCK1 to Disrupt Tight Junctions
2026-09-15
Ren et al. identify a mechanistic link between MVC VP2 and ROCK1, showing that early RhoA/ROCK1/MLC2 activation contracts the actomyosin network, redistributes Occludin, and promotes viral entry. The study provides a useful framework for investigating tight-junction regulation and highlights pathway-directed intervention points, while its conclusions remain primarily limited to an in vitro canine-cell model.
-
Pazopanib: From Angiogenesis to Genotype-Aware Translation
2026-09-14
Pazopanib (GW-786034) offers translational researchers more than a conventional anti-angiogenic probe. By inhibiting VEGFR, PDGFR, FGFR, and related receptor tyrosine kinases, it connects vascular biology with tumor-cell signaling and genotype-aware response hypotheses. This article integrates product-level mechanistic evidence with findings from ATRX-deficient high-grade glioma models, providing a practical framework for assay design, combination studies, biomarker stratification, and research-use interpretation.
-
A 83-01 in Corneal Fibrosis Research
2026-09-14
A 83-01 is an ALK-5 inhibitor that enables causal dissection of TGF-β/SMAD3 signaling in corneal fibrosis. This article translates recent LMCD1 findings into practical assay-design decisions while defining the compound’s selectivity, limitations, and experimental value.